|
1
|
Surh YJ: Cancer chemoprevention with
dietary phytochemicals. Nat Rev Cancer. 3:768–780. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Goel A, Kunnumakkara AB and Aggarwal BB:
Curcumin as ‘Curecumin’: from kitchen to clinic. Biochem Pharmacol.
75:787–809. 2008.
|
|
3
|
Hatcher H, Planalp R, Cho J, Torti FM and
Torti SV: Curcumin: from ancient medicine to current clinical
trials. Cell Mol Life Sci. 65:1631–1652. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shim JS, Kim DH, Jung HJ, et al:
Hydrazinocurcumin, a novel synthetic curcumin derivative, is a
potent inhibitor of endothelial cell proliferation. Bioorg Med
Chem. 10:2987–2992. 2002. View Article : Google Scholar
|
|
5
|
Rathore R, Jain JP, Srivastava A, et al:
Simultaneous determination of hydrazinocurcumin and phenol red in
samples from rat intestinal permeability studies: HPLC method
development and validation. J Pharm Biomed Anal. 46:374–380. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kakudo Y, Shibata H, Otsuka K, Kato S and
Ishioka C: Lack of correlation between p53-dependent
transcriptional activity and the ability to induce apoptosis among
179 mutant p53s. Cancer Res. 65:2108–2114. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar
|
|
8
|
Heng MC: Curcumin targeted signaling
pathways: basis for anti-photoaging and anti-carcinogenic therapy.
Int J Dermatol. 49:608–622. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu H and Jove R: The STATs of cancer - new
molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Alas S and Bonavida B: Inhibition of
constitutive STAT3 activity sensitizes resistant non-Hodgkin's
lymphoma and multiple myeloma to chemotherapeutic drug-mediated
apoptosis. Clin Cancer Res. 9:316–326. 2003.
|
|
11
|
Buettner R, Mora L and Jove R: Activated
STAT signaling in human tumors provides novel molecular targets for
therapeutic intervention. Clin Cancer Res. 8:945–954.
2002.PubMed/NCBI
|
|
12
|
Shen Y, Devgan G, Darnell JJ and Bromberg
J: Constitutively activated Stat3 protects fibroblasts from serum
withdrawal and UV-induced apoptosis and antagonizes the
proapoptotic effects of activated Stat1. Proc Natl Acad Sci USA.
98:1543–1548. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Real P, Sierra A, De Juan A, Segovia J,
Lopez-Vega J and Fernandez-Luna J: Resistance to chemotherapy via
Stat3- dependent overexpression of Bcl-2 in metastatic breast
cancer cells. Oncogene. 21:7611–7618. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang T, Niu G, Kortylewski M, et al:
Regulation of the innate and adaptive immune responses by Stat-3
signaling in tumor cells. Nat Med. 10:48–54. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Aggarwal BB and Shishodia S: Molecular
targets of dietary agents for prevention and therapy of cancer.
Biochem Pharmacol. 71:1397–1421. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bharti A, Donato N and Aggarwal B:
Curcumin (diferuloylmethane) inhibits constitutive and
IL-6-inducible STAT3 phosphorylation in human multiple myeloma
cells. J Immunol. 171:3863–3871. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bowman T, Garcia R, Turkson J and Jove R:
STATs in oncogenesis. Oncogene. 19:2474–2488. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kaptein A, Paillard V and Saunders M:
Dominant negative stat3 mutant inhibits interleukin-6-induced
Jak-STAT signal transduction. J Biol Chem. 271:5961–5964. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Faruqi T, Gomez D, Bustelo X, Bar-Sagi D
and Reich N: Rac1 mediates STAT3 activation by autocrine IL-6. Proc
Natl Acad Sci USA. 98:9014–9019. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bromberg J and Darnell JE Jr: The role of
STATs in transcriptional control and their impact on cellular
function. Oncogene. 19:2468–2473. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bromberg JF, Wrzeszczynska MH, Devgan G,
Zhao Y, Pestell RG, Albanese C and Darnell JE Jr: Stat3 as an
oncogene. Cell. 98:295–303. 1999. View Article : Google Scholar
|
|
22
|
Catlett-Falcone R, Landowski TH, Oshiro
MM, et al: Constitutive activation of Stat3 signaling confers
resistance to apoptosis in human U266 myeloma cells. Immunity.
10:105–115. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Epling-Burnette PK, Lui JH,
Catlette-Falcone R, et al: Inhibition of STAT3 signaling leads to
apoptosis of leukemic large granular lymphocytes and decreased
Mcl-1 expression. J Clin Invest. 107:351–362. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Alas S and Bonavida B: Rituximab
inactivates signal transducer and activation of transcription 3
(STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of
the interleukin 10 autocrine/paracrine loop and results in
down-regulation of Bcl-2 and sensitization to cytotoxic drugs.
Cancer Res. 61:5137–5144. 2001.PubMed/NCBI
|
|
25
|
Gritsko T, Williams A, Turkson J, et al:
Persistent activation of stat3 signaling induces survivin gene
expression and confers resistance to apoptosis in human breast
cancer cells. Clin Cancer Res. 12:11–19. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Diaz N, Minton S, Cox C, et al: Activation
of stat3 in primary tumors from high-risk breast cancer patients is
associated with elevated levels of activated SRC and survivin
expression. Clin Cancer Res. 12:20–28. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bromberg JF: Activation of STAT proteins
and growth control. Bioessays. 23:161–169. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Darnell JE Jr: Transcription factors as
targets for cancer therapy. Nat Rev Cancer. 2:740–749. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Darnell JE: Validating Stat3 in cancer
therapy. Nat Med. 11:595–596. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Turkson J: STAT proteins as novel targets
for cancer drug discovery. Expert Opin Ther Targets. 8:409–422.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim DJ, Chan KS, Sano S and Digiovanni J:
Signal transducer and activator of transcription 3 (Stat3) in
epithelial carcinogenesis. Mol Carcinog. 46:725–731. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xi S, Gooding WE and Grandis JR: In vivo
antitumor efficacy of STAT3 blockade using a transcription factor
decoy approach:implications for cancer therapy. Oncogene.
24:970–979. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Niu G, Wright KL, Huang M, et al:
Constitutive Stat3 activity upregulates VEGF expression and tumor
angiogenesis. Oncogene. 21:2000–2008. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xie TX, Huang FJ, Aldape KD, et al:
Activation of Stat3 in human melanoma promotes brain metastasis.
Cancer Res. 66:3188–3196. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lin L, Hutzen B, Ball S, et al: New
curcumin analogues exhibit enhanced growth-suppressive activity and
inhibit AKT and signal transducer and activator of transcription 3
phosphorylation in breast and prostate cancer cells. Cancer Sci.
100:1719–1727. 2009. View Article : Google Scholar
|
|
36
|
Dechow TN, Pedranzini L, Leitch A, et al:
Requirement of matrix metalloproteinase-9 for the transformation of
human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci USA.
101:10602–10607. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xie TX, Wei D, Liu M, et al: Stat3
activation regulates the expression of matrix metalloproteinase-2
and tumor invasion and metastasis. Oncogene. 23:3550–3560. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Boise LH, Gonzalez-Garcia M, Postema CE,
et al: Bcl-x, a bcl-2-related gene that functions as a dominant
regulator of apoptotic cell death. Cell. 74:597–608. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gonzalez-Garcia M, Perez-Ballestero R,
Ding L, et al: Bcl-xL is the major bcl-x mRNA form expressed during
murine development and its product localizes to mitochondria.
Development. 120:3033–3042. 1994.PubMed/NCBI
|
|
40
|
Grad JM, Zeng XR and Boise LH: Regulation
of Bcl-xL: a little bit to this and a little bit to STAT. Curr Opin
Oncol. 12:543–549. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhou P, Qian L, Kozopas KM and Craig RW:
Mcl-1, a bcl-2 family member, delays the death of hematopoietic
cells under a variety of apoptosis-inducing conditions. Blood.
89:630–643. 1997.PubMed/NCBI
|
|
42
|
Altieri DC: Validating survivin as a
cancer therapeutic target. Nat Rev Cancer. 3:46–54. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Calo V, Migliavacca M, Bazan V, et al:
STAT proteins: from normal control of cellular events to
tumorigenesis. J Cell Physiol. 197:157–168. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Maofu FU, Wang C, Li Z, Sakamaki T and
Pestell RG: Minireview: cyclin D1: normal and abnormal functions.
Endocrinology. 145:5439–5447. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Spencer CA and Groudine M: Control of
c-myc regulation in normal and neoplastic cells. Adv Cancer Res.
56:1–48. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Marcu KB, Bossone SA and Patel AJ: Myc
function and regulation. Annu Rev Biochem. 61:809–860. 1992.
View Article : Google Scholar
|
|
47
|
Facchini LM and Penn LZ: The molecular
role of Myc in growth and transformation: recent discoveries lead
to new insights. FASEB J. 12:633–651. 1998.PubMed/NCBI
|
